The Biosimilars Market spans FDA and EMA approved products across several biologic classes and reaches patients through hospital, retail, specialty and online channels. Polaris Market Research reports a market size of USD 35.22 billion in 2025 and USD 37.54 billion in 2026, with a projection of USD 73.24 billion by 2036 at a 6.9% CAGR from 2026 to 2036. Commercial adoption depends on regulatory approval, payer policy, formulary placement, physician prescribing, pricing and supply. This article looks at the classes, channels and partnerships that determine how products reach the market.
Monoclonal Antibodies Lead the Drug Class Landscape
Monoclonal antibodies held approximately 46.18% of the market in 2025, making them the leading drug class. The category benefits from wide commercialization across established products such as adalimumab and ustekinumab, and development of pembrolizumab, nivolumab and other antibody-based programs is expected to intensify competition. Other classes round out the picture: TNF-alpha inhibitors accounted for an estimated 14.72%, insulins for 11.36%, G-CSF agents for 9.84% and other classes such as growth hormone and erythropoietin for 9.14%. ENNUMO became the eighth US pegfilgrastim biosimilar in May 2026, adding price pressure in supportive oncology care.
VEGF Inhibitors and the Ophthalmology Opportunity
VEGF inhibitors are projected to register the highest drug class CAGR at 8.12% during 2026 to 2036, supported by growing competition in ophthalmology. Aflibercept is the key reference product, and Formycon and Klinge, Samsung Bioepis, Sandoz, Celltrion, Biocon and Amgen all have FDA approved biosimilars. Long-term treatment needs for chronic retinal diseases create repeat demand, and regulatory approvals and commercial launches can increase treatment options and competitive pressure. Ophthalmology held about 9.83% of the market in 2025 and is expected to grow at a 7.72% CAGR. Alvotech's high-dose aflibercept biosimilar is in confirmatory trials, and Teva's aflibercept biosimilar AHZANTIVE reached patients in France, Germany, Spain and the Netherlands from May 2026.
Biosimilar Manufacturing Complexity and Capacity
Biosimilar manufacturing demands specialized facilities, cell-line development, analytical characterization, process validation and comparative evidence, which makes it more complex than conventional generic production. These requirements raise investment needs and make entry harder for smaller manufacturers, which is why they often partner or exit. Barriers to entry also include comparative development costs, intellectual property and litigation risk, and supply chain exposure to tariffs and logistics when importing. Originator rebate strategies can also limit price advantage, because a lower list price does not necessarily translate into a lower net cost of treatment.
Companies are responding with new operating models. Henlius handles development, manufacturing and supply of its Sandoz programs through its own biologics platform. EirGenix reported FDA and EMA feedback supporting an abbreviated pathway for EG1206A, including a possible waiver of Phase 3 comparative efficacy trials. Capacity now matters as much as trial data.
𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
https://www.polarismarketresearch.com/industry-analysis/biosimilars-market
Hospital Pharmacies and Retail Channels
Hospital pharmacies held the largest distribution share at around 58.37% in 2025. Infused biosimilars used in oncology and other clinical settings drive the channel, supported by institutional purchasing, centralized procurement, formulary management and supervised administration. Hospitals and oncology buying groups contract on price, clinical coverage and continuity of supply, and each new approval gives them another product to contract against. Retail and specialty pharmacies together accounted for 34.21% of the market, while online and cash-pay platforms held 7.42% and are expected to grow at a 9.26% CAGR from 2026 to 2036. Specialty pharmacies provide patient education, cold-chain logistics, adherence programs, delivery and reimbursement services to support biologics. Pharmacy benefit managers focus on rebates and formulary position.
Licensing and Commercialization Partnerships Expand Reach
Licensing and commercialization partnerships give manufacturers regulatory expertise, healthcare networks and distribution capability they would otherwise have to build. On 17 August 2026, Henlius granted Sandoz exclusive rights outside China to up to 10 mAb and ADC biosimilars, in a deal worth up to USD 322 million, lifting Sandoz's pipeline to 39 assets. In June 2026, EirGenix signed an agreement to commercialize its pertuzumab biosimilar EG1206A in Japan. On 17 September 2026, Shilpa Biologicals signed an exclusive licence with Saudi Arabia's SPIMACO Bio for PD-1 inhibitor biosimilars across MENA, with phased technology transfer intended to build local manufacturing and support Vision 2030 localization goals.
Regional partnerships can also help manufacturers reduce development and commercialization costs across markets. These deals help explain regional growth rates. Asia Pacific is projected to grow at an 8.47% CAGR and the Middle East & Africa at 7.56%, while Latin America accounted for around 4.11% of the market in 2025.
Key Players
Key players named in the report include Accord BioPharma Inc., Alvotech S.A., Amgen Inc., Amneal Pharmaceuticals, Inc., Biocon Biologics Ltd., Bio-Thera Solutions, Ltd., Boehringer Ingelheim International GmbH, Celltrion, Inc., Dr. Reddy's Laboratories Ltd., EirGenix, Inc., Formycon AG, Fresenius Kabi AG, mAbxience Holdings S.L., Organon & Co., Pfizer Inc., Samsung Bioepis Co., Ltd., Sandoz Group AG, Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd. and Zydus Lifesciences Limited.
Conclusion
In the Biosimilars Market, success depends on more than a clinical data package. Drug class, channel strategy, production capability and partnerships each influence whether a product converts approval into access. Companies that align these elements with payer and procurement realities will be better positioned as the market grows toward USD 73.24 billion by 2036.
More Trending Latest Reports By Polaris Market Research:
Specialty Oilfield Chemicals Market
Law Enforcement Software Market
Fintech as a Service (FaaS) Market
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek